ASG Eye Hospital expands eye care network with 11 strategic partnerships

IMT News Desk
IMT News Desk
· 2 min read

The partnerships are with 11 esteemed hospitals across six Indian states, particularly in Tier-II and Tier-III cities

ASG Eye Hospital announced further expansion of its eye care network through partnerships with 11 esteemed hospitals across six Indian states, particularly in Tier-II and Tier-III cities. These new collaborations with accomplished clinical practices are in line with ASG’s long-term vision to grow its eye care footprint and further enhance accessibility to standardised best in class eye care in regions that need it the most.

Dr Arun Singhvi, MD and CEO,  ASG Eye Hospital said, “Every collaboration we consider is driven by the goal of taking quality eye care to communities that need it the most, while maintaining standardized and advanced technology in the field. The partners we pick are highly regarded in the field of ophthalmology and together, we aim to bring best-in-class services closer to home, backed by a patient-centered approach and a shared vision of care.”

The new partner locations include:

1. Dr Gadgil Eye Hospital, Thane, Maharashtra – Dr Uday Gadgil, 2 locations in Thane.

2. Mansa ASG Eye Hospital, Sikar, Rajasthan – Dr Narendra Chouhan.

3. Apex Eye Hospital & Research Centre, Jaunpur, Uttar Pradesh – Dr Niranjan Kumar Singh.

4. Modern Eye Care, Gaya, Bihar – Dr Mohammad Haroon Rashid.

5. Khurana Eye Centre, Rohtak, Haryana – Dr Aruj Khurana and Dr Bhawna Khurana.

6. Drishti Eye Clinic, Virar (MMR), Maharashtra – Dr Hemantkumar Chasia

7.Bavishi Eye Hospitals, Ahmedabad, Gujarat – Dr Darshin Bavishi and Dr Alaap Bavishi new locations – Nehru Nagar, Relief Road, Isnapur, and a new Centre of Excellence on SG Highway.

Read Next

India successfully validates the first indigenous HPV test for Cervical Cancer screening
News
June 13, 2026

India successfully validates the first indigenous HPV test for Cervical Cancer screening

India has achieved a significant milestone in cervical cancer prevention with the successful validation of the country’s first indigenous HPV DNA tests, which meet international standards for cervical cancer screening. Published in the International Journal of Cancer, a multicentre study involving leading Indian and international institutions found that Molbio Diagnostics Truenat HPV-HR Plus met the […]
Article by: IMT News Desk
Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk